Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism
and account for less than 2% of all pituitary adenomas. In the last years, the diagnosis has …

Context: Although pituitary tumors are common, pituitary carcinoma is very rare and is only
diagnosed when pituitary tumor noncontiguous with the sellar region is demonstrated …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Hyperthyroidism is mainly due to autoimmune thyroid disorders or toxic goiter, and very
rarely to the presence of thyrotropin (TSH)-secreting pituitary adenomas (TSHomas). These …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Inappropriate secretion of TSH was first described in 1960 in a patient with evidence of
hyperthyroidism and expanded sella on imaging. It was later found that a type of pituitary …

Abstract Thyrotropin (TSH)-secreting adenomas (TSHomas) are the rarest form of pituitary
adenomas, and most endocrinologists will see few cases in a lifetime, if any. In most cases …

Pituitary carcinoma is a rare disease, defined by the presence of cerebrospinal or distant
metastasis of a pituitary neuroendocrine tumor (PitNET). To review our institutional …

Purpose Pituitary tumors are the second most common intracranial tumors, however,
pituitary carcinoma is a rare clinical entity which represents only 0.1–0.2% of all pituitary …

Purpose The purpose of this work was toinvestigate the clinicopathological characteristics at
the initial diagnosis of the pituitary tumor and at pituitary carcinoma (PC) diagnosis …